Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONTRAFECT CorpCFRX · Entity 116797 | Chief Financial Officer | February 14, 2023 | February 16, 2023 |
| SeaStar Medical Holding CorpICU · Entity 7863 | Chief Financial Officer | August 18, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONTRAFECT Corp
Report date February 14, 2023 · Filed February 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2033-02-14 | Direct | 25,000 |
Reported balance
After 2023-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-14 · Grant · Acquired 25,000 · Balance 25,000 F1: (1) The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date.
SeaStar Medical Holding Corp
Report date August 18, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 2,500 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 750 · Balance 2,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 19, 2026 20:21 UTC | SeaStar Medical Holding Corp ICU · Entity 7863 | PurchaseCommon Stock, par value $0.0001 | 750 | $3.27 | $2,452.50 |
DisclosureSEC source: 0001437749-26-028540 · rdgdoc.xml · nonDerivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:49 UTC | SeaStar Medical Holding Corp ICU · Entity 7863 | PurchaseCommon Stock | 14,500 | $0.35 | $5,098.20 |
DisclosureSEC source: 0001437749-25-037589 · rdgdoc.xml · nonDerivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 20:09 UTC | CONTRAFECT Corp CFRX · Entity 116797 | GrantOptions (Right to Buy) · Derivative | 25,000 | $5.04 Strike: $5.04 | $126,000.00 |
DisclosureSEC source: 0001209191-23-010323 · doc4.xml · derivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: (1) The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 18:13 UTC | CONTRAFECT Corp CFRX · Entity 116797 | GrantOptions (Right to Buy) · Derivative | 165,000 | $3.33 Strike: $3.33 | $549,450.00 |
DisclosureSEC source: 0001209191-22-010959 · doc4.xml · derivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date. Read SEC document |
| April 08, 2021 Filed Apr 14, 2021 21:38 UTC | CONTRAFECT Corp CFRX · Entity 116797 | GrantOptions (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-026754 · doc4.xml · derivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 16:54 UTC | CONTRAFECT Corp CFRX · Entity 116797 | GrantOptions (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001209191-20-036644 · doc4.xml · derivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on June 11, 2021 and then 1/16 of the total shares vest quarterly thereafter, subject to continued service to the issuer through each vesting date. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 06:28 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseCommon Stock, par value $0.0001 per share | 5,000 | $0.37 | $1,850.00 |
DisclosureSEC source: 0001209191-19-060539 · doc4.xml · nonDerivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,091 F1 · kind: The purchase reported in this Form 4 was made on the open market. F2 · price: The price reported is a weighted average price based on the shares purchased in multiple transactions. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price comprising the average set forth herein. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:52 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseWarrants (Right to Buy) · Derivative | 400 | $0.01 Strike: $1.55 | $4.00 |
DisclosureSEC source: 0001209191-17-046330 · doc4.xml · derivative · entry 2 Messinger Michael · CIK 0001615039 · SVP Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Stock, par value $0.0001 per share · 400 shares Expires 2022-07-25 Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 16:52 UTC | CONTRAFECT Corp CFRX · Entity 116797 | PurchaseCommon Stock, par value $0.0001 per share | 800 | $1.24 | $992.00 |
DisclosureSEC source: 0001209191-17-046330 · doc4.xml · nonDerivative · entry 1 Messinger Michael · CIK 0001615039 · SVP Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,091 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.